Amerika Serikat - Inggris - NLM (National Library of Medicine)

slate run pharmaceuticals, llc - eptifibatide (unii: na8320j834) (eptifibatide - unii:na8320j834) - eptifibatide injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (mi) in patients with acs (unstable angina [ua]/non-st-elevation myocardial infarction [nstemi]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (pci). eptifibatide injection is indicated to decrease the rate of a combined endpoint of death, new mi, or need for urgent intervention in patients undergoing pci, including those undergoing intracoronary stenting [see clinical studies ( 14.1, 14.2)] . treatment with eptifibatide injection is contraindicated in patients with: - a history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days - severe hypertension (systolic blood pressure >200 mm hg or diastolic blood pressure >110 mm hg) not adequately controlled on antihyperten

Amerika Serikat - Inggris - NLM (National Library of Medicine)

mylan institutional llc - eptifibatide (unii: na8320j834) (eptifibatide - unii:na8320j834) - eptifibatide injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (mi) in patients with acs (unstable angina [ua]/non-st- elevation myocardial infarction [nstemi]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (pci). eptifibatide injection is indicated to decrease the rate of a combined endpoint of death, new mi, or need for urgent intervention in patients undergoing pci, including those undergoing intracoronary stenting [see clinical studies (14.1, 14.2)] . treatment with eptifibatide is contraindicated in patients with: risk summary available data on eptifibatide use in pregnant women from published literature and the pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. untreated myocardial infarction can be fatal to the pregnant woman and fetus (see clinical considerations) . in animal reproduc

Amerika Serikat - Inggris - NLM (National Library of Medicine)

hainan shuangcheng pharmaceuticals co., ltd. - eptifibatide (unii: na8320j834) (eptifibatide - unii:na8320j834) - eptifibatide injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (mi) in patients with acs (unstable angina [ua]/non-st-elevation myocardial infarction [nstemi]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (pci). eptifibatide injection is indicated to decrease the rate of a combined endpoint of death, new mi, or need for urgent intervention in patients undergoing pci, including those undergoing intracoronary stenting [see clinical studies (14.1, 14.2)] . treatment with eptifibatide is contraindicated in patients with: - a history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days - severe hypertension (systolic blood pressure >200 mm hg or diastolic blood pressure >110 mm hg) not adequately controlled on antihypertensive therapy - major surgery within the preceding 6 weeks - history of stroke within 30 days or any history of hemorrhagic stroke - current o

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

viatris limited - eptifibatide 0.75 mg/ml (75 mg in 100 ml) - solution for infusion - 0.75 mg/ml - active: eptifibatide 0.75 mg/ml (75 mg in 100 ml) excipient: citric acid monohydrate sodium hydroxide water for injection - indicated for patients undergoing non-urgent, percutaneous coronary intervention (pci) with coronary stenting for the reduction of death, myocardial infarction, urgent revascularisation and the need for acute antithrombotic rescue therapy. indicated for the reduction of death and myocardial infarction in patients presenting with unstable angina or non-q-wave myocardial infarction. indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. eptifibatide is intended for use with aspirin, heparin or clopidigrel.

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

viatris limited - eptifibatide 2 mg/ml (20 mg in 10 ml) - solution for injection - 2 mg/ml - active: eptifibatide 2 mg/ml (20 mg in 10 ml) excipient: citric acid monohydrate sodium hydroxide water for injection - indicated for patients undergoing non-urgent, percutaneous coronary intervention (pci) with coronary stenting for the reduction of death, myocardial infarction, urgent revascularisation and the need for acute antithrombotic rescue therapy. indicated for the reduction of death and myocardial infarction in patients presenting with unstable angina or non-q-wave myocardial infarction. indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. eptifibatide is intended for use with aspirin, heparin or clopidigrel.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

usv private limited - eptifibatide (unii: na8320j834) (eptifibatide - unii:na8320j834) - eptifibatide injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (mi) in patients with acs (unstable angina [ua]/non-st-elevation myocardial infarction [nstemi]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (pci). eptifibatide injection is indicated to decrease the rate of a combined endpoint of death, new mi, or need for urgent intervention in patients undergoing pci, including those undergoing intracoronary stenting [see clinical studies (14.1, 14.2)] . treatment with eptifibatide injection is contraindicated in patients with:  - a history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days - severe hypertension (systolic blood pressure >200 mm hg or diastolic blood pressure >110 mm hg) not adequately controlled on antihypertensive therapy - major surgery within the preceding 6 weeks - history of stroke within 30 days or any history of hemorrhagic stroke

Amerika Serikat - Inggris - NLM (National Library of Medicine)

usv private limited - eptifibatide (unii: na8320j834) (eptifibatide - unii:na8320j834) - eptifibatide injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (mi) in patients with acs (unstable angina [ua]/non-st-elevation myocardial infarction [nstemi]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (pci). eptifibatide injection is indicated to decrease the rate of a combined endpoint of death, new mi, or need for urgent intervention in patients undergoing pci, including those undergoing intracoronary stenting [see clinical studies (14.1, 14.2)] . treatment with eptifibatide injection is contraindicated in patients with:  - a history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days - severe hypertension (systolic blood pressure >200 mm hg or diastolic blood pressure >110 mm hg) not adequately controlled on antihypertensive therapy - major surgery within the preceding 6 weeks - history of stroke within 30 days or any history of hemorrhagic stroke

Israel - Inggris - Ministry of Health

a.l. medi-market ltd. - eptifibatide - solution for infusion - eptifibatide 0.75 mg / 1 ml - eptifibatide - eptifibatide medi-market is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. eptifibatide medi-market is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. eptifibatide medi-market is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). eptifibatide medi-market is intended for use with aspirin and heparin.

Israel - Inggris - Ministry of Health

a.l. medi-market ltd. - eptifibatide - solution for injection - eptifibatide 2 mg / 1 ml - eptifibatide - eptifibatide medi-market is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. eptifibatide medi-market is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. eptifibatide medi-market is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). eptifibatide medi-market is intended for use with aspirin and heparin.

Kanada - Inggris - Health Canada

teva canada limited - eptifibatide - solution - 2mg - eptifibatide 2mg - platelet aggregation inhibitors